Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元，同比减少99.27%

自选股智能写手05-18

3月31日，Supernus Pharmaceuticals, Inc.（SUPN.US）公布财报，公告显示公司2024财年第一财季净利润为124000.00美元，同比减少99.27%；其中营业收入为1.44亿美元，同比减少6.49%，每股基本收益为0.00美元。从资产负债表来看，Supernus Pharmaceuticals, Inc.（SUPN.US）总负债3.75亿美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2436365946?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-18 00:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2436365946","market":"us","top_or_hot":-1,"title":"Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元，同比减少99.27%","media":"自选股智能写手","content":"<div>\n<p>3月31日，Supernus Pharmaceuticals, Inc.（SUPN.US）公布财报，公告显示公司2024财年第一财季净利润为124000.00美元，同比减少99.27%；其中营业收入为1.44亿美元，同比减少6.49%，每股基本收益为0.00美元。从资产负债表来看，Supernus Pharmaceuticals, Inc.（SUPN.US）总负债3.75亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元，同比减少99.27%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupernus Pharmaceuticals, Inc.2024财年第一财季实现净利润124000.00美元，同比减少99.27%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-18 00:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月31日，Supernus Pharmaceuticals, Inc.（SUPN.US）公布财报，公告显示公司2024财年第一财季净利润为124000.00美元，同比减少99.27%；其中营业收入为1.44亿美元，同比减少6.49%，每股基本收益为0.00美元。从资产负债表来看，Supernus Pharmaceuticals, Inc.（SUPN.US）总负债3.75亿美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b","article_id":"2436365946","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405180008078774faec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2436365946","pubTimestamp":1715962078,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月31日，Supernus Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第一财季净利润为124000.00美元，同比减少99.27%；其中营业收入为1.44亿美元，同比减少6.49%，每股基本收益为0.00美元。机构评级：截至2024年3月31日，当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为40.50美元，其中最低目标价为38.00美元，最高目标价为43.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"Supernus Pharmaceuticals, Inc. achieved a net profit of US $124,000.00 in the first quarter of fiscal year 2024, a year-on-year decrease of 99.27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"3月31日，Supernus Pharmaceuticals, Inc.（SUPN.US）公布财报，公告显示公司2024财年第一财季净利润为124000.00美元，同比减少99.27%；其中营业收入为1.44亿美元，同比减少6.49%，每股基本收益为0.00美元。从资产负债表来看，Supernus Pharmaceuticals, Inc.（SUPN.US）总负债3.75亿美元，其中短期债务9.13百万美元，资产负债比为3.48，流动比率为1.73。机构评级：截至2024年3月31日，当前有4家机构对Supernus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为40.50美元，其中最低目标价为38.00美元，最高目标价为43.00美元。公司简介：Supernus Pharmaceuticals Inc 是一家专业制药公司，致力于开发和商业化治疗包括神经和精神疾病在内的中枢神经系统疾病的产品。 该公司多样化的神经科学产品组合包括癫痫、偏头痛、注意力缺陷多动障碍(ADHD)、帕金森病(PD)的运动障碍、宫颈肌张力障碍、慢性唾液分泌、PD患者接受左旋多巴治疗的运动障碍，以及成人患者药物诱导的锥体外系反应。公司产品包括 Trokendi XR、Oxtellar XR、Qelbree、APOKYN、XADAGO、MYOBLOC、GOCOVRI 和 Osmolex ER。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2436365946"}